CAS: 1060816-22-9; Ethyl 2-Bromooxazole-5-Carboxylate

相似化合物

1998215-93-2 78451-13-5 118994-89-1

上下游产品

噁唑-5-羧酸乙酯 Oxazol-5-Yl-Carboxylic Acid Ethyl Ester 118994-89-1

噁唑-5-羧酸乙酯置于lithium Hexamethyldisilazane,四溴化碳体系中,用 四氢呋喃 用作溶剂,化学反应 2.17H,以68%的收率获得2-溴恶唑-5-甲酸乙酯
参考文献:一种2-溴恶唑-5-甲酸乙酯的合成方法
标题:一种2-溴恶唑-5-甲酸乙酯的合成方法
摘要:本发明公开了一种2‑溴恶唑‑5‑甲酸乙酯的合成方法.该方法为:以恶唑‑5‑羧酸乙酯为原料,经过碱拔氢后再与溴化试剂反应得到2‑溴恶唑‑5‑甲酸乙酯.虽然2‑溴恶唑‑5‑甲酸乙酯用于药物合成的报道有很多,但其合成路线却未见报道.本发明首次提出了合成路线,以较高的收率和高纯度制得2‑溴恶唑‑5‑甲酸乙酯.

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.